BioSpace News Archive

bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company’s September 6, 2022, public offering of securities.

Sight Sciences, Inc., announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery during this year’s annual AAO convention at McCormick Place in Chicago, IL.

Citius Pharmaceuticals, Inc. today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

HeartBeam, Inc. announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the United States Patent and Trademark Office.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that ASTRUM-005, an international multi-centre study led by Professor Ying Cheng, has been published in The Journal of the American Medical Association (JAMA, impact factor of 157.3), one of the top four medical journals in the world.

Brand Institute is proud to announce its work with Heron Therapeutics in developing the brand name APONVIE™, which was approved by the FDA September 16, 2022.

Point Robotics MedTech Inc. (Point Robotics), a rising star in the field of orthopedic surgery, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its minimally invasive surgical robot, POINT™ Kinguide Robotic-Assisted Surgical System, in August.

CNS Pharmaceuticals today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

Niron Magnetics today announced the expansion of its management team with the appointments of David Northall, vice president, global operations, Carlijn Mulder, Ph.D.

Qnovia, Inc. today announced it has raised $17 million in Series A funding.